Payment overview · 2025
General Payments
$227.57
12 reported records · 6 companies
Healthcare provider profile · identity verified
Alison E Bilyeu, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOWEAQUA, IL · NPI 1568474823
Verified facts
What the public records show
CMS Open Payments records show Alison E Bilyeu, MD received $227.57 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.52 | 31.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.73 | 25.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.98 | 14.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.61 | 10.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.63 | 9.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.10 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.57 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.73 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.80 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 126 |
| Omeprazole | Omeprazole | 407 | 112 |
| Lisinopril | Lisinopril | 389 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 112 |
| Gabapentin | Gabapentin | 373 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 82 |
| Losartan Potassium | Losartan Potassium | 315 | 86 |
| Metformin Hcl | Metformin Hcl | 311 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 85 |
| Prednisone | Prednisone | 265 | 185 |
| Sertraline Hcl | Sertraline Hcl | 246 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 227 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 66 |
| Alprazolam | Alprazolam | 219 | 45 |
| Simvastatin | Simvastatin | 195 | 45 |
| Eliquis | Apixaban | 190 | 32 |
| Potassium Chloride | Potassium Chloride | 184 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 183 | 56 |
| Montelukast Sodium | Montelukast Sodium | 178 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 41 |
| Tramadol Hcl | Tramadol Hcl | 162 | 43 |
| Carvedilol | Carvedilol | 157 | 45 |
| Famotidine | Famotidine | 157 | 53 |
| Fenofibrate | Fenofibrate | 150 | 37 |
| Alendronate Sodium | Alendronate Sodium | 147 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 57 |
| Warfarin Sodium | Warfarin Sodium | 144 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 27 |
| Meloxicam | Meloxicam | 140 | 34 |
| Allopurinol | Allopurinol | 137 | 40 |
| Glipizide | Glipizide | 137 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 22 |
| Clonazepam | Clonazepam | 129 | 22 |
| Lorazepam | Lorazepam | 129 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 29 |
| Furosemide | Furosemide | 121 | 37 |
| Atenolol | Atenolol | 116 | 30 |
| Jardiance | Empagliflozin | 116 | 26 |
| Torsemide | Torsemide | 100 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 42 |
| Cephalexin | Cephalexin | 93 | 74 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Ezetimibe | Ezetimibe | 87 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 83 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 42 |
| Metformin Hcl Er | Metformin Hcl | 79 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 20 |
| Bupropion Xl | Bupropion Hcl | 74 | 18 |
| Amoxicillin | Amoxicillin | 71 | 55 |
| Pregabalin | Pregabalin | 69 | 13 |
| Celecoxib | Celecoxib | 68 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 21 |
| Ozempic | Semaglutide | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Spironolactone | Spironolactone | 62 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 22 |
| Finasteride | Finasteride | 59 | 13 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 58 | 14 |
| Naproxen | Naproxen | 56 | 16 |
| Nystatin | Nystatin | 55 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 44 |
| Propranolol Hcl | Propranolol Hcl | 53 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 12 |
| Mupirocin | Mupirocin | 50 | 35 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Acyclovir | Acyclovir | 40 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Ondansetron Odt | Ondansetron | 39 | 22 |
| Meclizine Hcl | Meclizine Hcl | 37 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 25 |
| Fluconazole | Fluconazole | 30 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 22 |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 14 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Flunisolide | Flunisolide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.57 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, PAXLOVID, REPATHA, YUPELRI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error